30-Jul-2001 - Albany Molecular Research, Inc. (AMRI)

Shirley Ann Jackson, Ph.D. elected to Albany Molecular Research, Inc. Board of Directors

Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced the election of Shirley Ann Jackson, Ph.D. to its Board of Directors. This election fills a newly created position. A prominent physicist and university president, Dr. Jackson has served since 1999 as president of Rensselaer Polytechnic Institute, one of the nation's leading technological and research universities, located in Troy, New York. Before assuming the presidency at Rensselaer, she was chairman of the U.S. Nuclear Regulatory Commission (NRC) from 1995-1999 under former President Clinton, and a professor of physics at Rutgers University from 1991 to 1995. Dr. Jackson worked as a theoretical physicist at the former AT&T Bell Laboratories during the period 1976 to 1991. "We are delighted to have Dr. Jackson on our Board," said Albany Molecular Research, Inc. Chairman and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "Dr. Jackson brings a strong scientific background as a physicist and university administrator, along with extensive experience in industry, academia and government. She is a visionary leader and driven individual who has instituted significant change and improvement at Rensselaer. Her wisdom and experience will be valuable to AMRI." Soon after assuming leadership at Rensselaer, Dr. Jackson launched a comprehensive and ambitious strategic plan to enhance research and upgrade Rensselaer's status as a leading university, particularly in the areas of biotechnology and information technology. D'Ambra continued, "We think that Rensselaer's strategic focus in biotechnology research, along with related biotechnology research collaborations between Rensselaer and other university and government organizations in the Albany area, will provide excellent vehicles to strengthen academic and industrial ties locally." Dr. Jackson becomes the seventh member of the AMRI Board of Directors. She received her undergraduate degree from MIT in physics and a doctorate in theoretical physics from MIT in 1973. For 15 years, Dr. Jackson conducted research in theoretical physics, solid state and quantum physics, and optical physics at AT"T Bell Laboratories. While Dr. Jackson was a professor of physics at Rutgers from 1991 to 1995, she also served as a consultant to Bell Labs. In 1995, Dr. Jackson was appointed by former President Clinton as chairman of the US Nuclear Regulatory Commission, where she served until her appointment at Rensselaer. While at the NRC, Dr. Jackson was elected chair of the International Nuclear Regulators Association, which is composed of senior nuclear regulatory officials from Canada, France, Germany, Japan, Spain, Sweden, the United Kingdom and the United States. For four years, she represented the U.S. at the General Conference of the International Atomic Energy Agency in Vienna, Austria. Dr. Jackson is a member of the National Academy of Engineering and the American Academy of Arts and Sciences. She is a Life Member of the MIT Corporation (MIT's Board of Trustees). In addition to her position at AMRI, Dr. Jackson also serves as a director of FedEx Corporation, AT"T, Public Service Enterprise Group, Sealed Air Corporation, Newport News Shipbuilding, USX Corporation, and SCI Systems Inc.

Facts, background information, dossiers
  • biotechnology
  • Albany Molecular Research
  • United Kingdom
  • Sweden
  • Spain
  • Sealed Air
  • Germany
  • Bell
More about Albany Molecular Research
  • News

    AMRI to Close Holywell, U.K. API Manufacturing Facility

    AMRI announced that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and i ... more

    AMRI Opens New Research Facility in Budapest, Hungary

    AMRI announced that it has finished the construction of a new state-of-the-art chemistry R&D facility in Budapest, Hungary. The successful completion and move into 32,300 square feet (3,000 square meters) of laboratory and administrative space marks a significant milestone in the company’s ... more

    AMRI Names Senior Director, Analytical and Quality Services

    AMRI announced that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008. Dr. Guo will oversee a ... more

  • Companies

    Albany Molecular Research, Inc. (AMRI)

    Founded in 1991 as Albany Molecular Research, Inc., AMRI provides scientific services, products and technologies focused on improving the quality of life. The company has steadily evolved, with global facilities now in the United States, Europe and Asia. Its 1,200+ employees have the expe ... more